Viscient Biosciences
- Biotech or pharma, therapeutic R&D
Viscient is clinical stage biotech advancing two liver fibrosis (MASH) drugs. Two antifibrotic small molecules available for partnering. Lead drug entering Phase 2 2026 for MASH, novel target. Second drug - Preclinical antifibrotic drug to novel target, shows approx. 40% reduction of fibrosis in preclinical models of disease. Both targets are well validated and both drugs show strong effects in proprietary NAM organoid models of disease made from primary cells from patients with MASH and as published in 2024 with Dr. David Brenner of UCSD-Sanford Burnham.
Targets available for disclosure during partnering discussions.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}